Graypoint LLC’s Moderna MRNA Stock Holding History

Graypoint LLC’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,114	Closed	-$251K	–	500
2024 Q2	$251K	Buy	+2,114	New	+$268K	0.02%	416
2023 Q1	–	Sell	-1,392	Closed	-$250K	–	365
2022 Q4	$250K	Buy	+1,392	New	+$228K	0.03%	293

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Graypoint LLC's MRNA Position: Q3 2024 in Review

Graypoint LLC sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,114 shares — an estimated $251K sold.

Graypoint LLC first reported a position in MRNA in Q4 2022 and held it in 2 quarters. The position peaked at $251K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

Graypoint LLC reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
Graypoint LLC sold 2,114 Moderna shares in Q3 2024, an estimated $251K.
Graypoint LLC first reported a position in Moderna in Q4 2022 and held it in 2 quarters.
Graypoint LLC's Moderna position peaked at $251K in Q2 2024.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Graypoint LLC's 13F filing for Q3 2024, filed 31 Oct 2024.